All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
The vector of anti-EGFR chimeric antigen receptor (CAR) is constructed for the engineering of T cells to target Human EGFR. The T cells are genetically modified through transduction with a lentiviral vector expressing scFv of anti-EGFR antibody linked to 4-1BB and CD3ζ signaling domains. And the vector product was designed for the treatment of Melanoma.
CAR Construction : Fig.1 P1X, P2X, and P3X are EGFR ligand antagonists. A-431 cells were treated with P1X, P2X, or P3X for 1 hour followed by 10-minute stimulation with 8 nmol/L EGF ligand. pEGFR was measured by ELISA, and results were plotted in units of mean fluorescence intensity (MFI). Kearns, J. D., Bukhalid, R., Sevecka, M., Tan, G., Gerami-Moayed, N., Werner, S. L., ... & Wolf, B. B. (2015). Enhanced Targeting of the EGFR Network with MM-151, an Oligoclonal Anti-EGFR Antibody TherapeuticEnhanced Inhibition of EGFR Signal Amplification by MM-151. Molecular Cancer Therapeutics, 14(7), 1625-1636. |
More Published Data More Published Data
There are currently no customer reviews or questions for Anti-EGFR (P2X) h(4-1BB-CD3ζ) CAR, pCDCAR1 (CAR-ZP8077). Click the button below to contact us or submit your feedback about this product.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION